Portfolio Holdings Detail for ISIN IE00BYXG2H39

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	BTEC(USD) LSE
ETF Ticker	BTEK(GBP) LSE
ETF Ticker	2B70(EUR) F
ETF Ticker	2B70.DE(EUR) CXE
ETF Ticker	BTEC.LS(USD) CXE
ETF Ticker	BTEK.LS(GBP) CXE
ETF Ticker	BTEC.L(GBP) LSE
ETF Ticker	BTEK.L(GBP) LSE

Holdings detail for LENZ

Show aggregate LENZ holdings

News associated with LENZ

Peek Under The Hood: ITOT Has 12% Upside

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-03 08:00:12

TD Asset Management Inc Sells 68,172 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)

TD Asset Management Inc decreased its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) by 66.2% during the first quarter, Holdings Channel reports. The firm owned 34,828 shares of the company’s stock after selling 68,172 shares during the quarter. TD Asset Management Inc’s holdings in LENZ Therapeutics were worth $895,000 as of […] - 2025-08-05 04:37:17

Noteworthy Wednesday Option Activity: META, CVNA, LENZ

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Meta Platforms Inc (Symbol: META), where a total volume of 348,474 contracts has been traded thus far today, a contract volume which is representative of approxi - 2025-07-16 17:13:46

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of “Buy” by Analysts

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) have been assigned an average rating of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year […] - 2025-06-26 03:10:50

Harbor Capital Advisors Inc. Has $1.25 Million Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Harbor Capital Advisors Inc. grew its holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) by 10.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 48,616 shares of the company’s stock after purchasing an additional 4,627 shares during the period. Harbor Capital Advisors Inc. […] - 2025-06-13 05:18:56

Jane Street Group LLC Cuts Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Jane Street Group LLC lessened its holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) by 34.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,938 shares of the company’s stock after selling 4,089 shares during the quarter. Jane Street Group LLC’s holdings in […] - 2025-06-05 04:15:01

The Manufacturers Life Insurance Company Raises Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

The Manufacturers Life Insurance Company grew its holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) by 116.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 67,891 shares of the company’s stock after buying an additional 36,582 shares during the period. The Manufacturers […] - 2025-05-12 05:36:48

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of “Buy” by Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) have been given an average recommendation of “Buy” by the six analysts that are currently covering the company, Marketbeat reports. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 […] - 2025-05-07 02:34:51

Geode Capital Management LLC Sells 3,998 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Geode Capital Management LLC cut its stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) by 1.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 334,026 shares of the company’s stock after selling 3,998 shares during the period. Geode Capital […] - 2025-04-24 04:24:51

LENZ Therapeutics (NASDAQ:LENZ) Shares Down 8.5% – Here’s Why

LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report)’s share price fell 8.5% during trading on Monday . The company traded as low as $18.81 and last traded at $19.38. 351,716 shares traded hands during trading, an increase of 104% from the average session volume of 172,211 shares. The stock had previously closed at $21.18. Analyst […] - 2025-04-08 04:56:51

Bank of New York Mellon Corp Trims Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Bank of New York Mellon Corp cut its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) by 1.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 29,214 shares of the company’s stock after selling 428 shares during the quarter. Bank of New York Mellon Corp’s holdings in LENZ Therapeutics were […] - 2025-03-26 05:52:54

TD Cowen Initiates Coverage on LENZ Therapeutics (NASDAQ:LENZ)

Equities research analysts at TD Cowen began coverage on shares of LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) in a research note issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating and a $60.00 price target on the stock. TD Cowen’s price target would suggest a potential upside of 135.11% from the company’s […] - 2025-03-20 04:48:55

Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target at $35.40

LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) has earned an average rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target […] - 2025-02-06 04:06:45

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) LENZ holdings

Share Trades of LENZ by Blackrock for IE00BYXG2H39

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-10-06	BUY	141	46.110	49.230	48.918	USD 6,897	29.64
2025-10-03	BUY	329	48.740	49.850	49.739	USD 16,364	29.54
2025-10-02	BUY	47	48.320	50.400	50.192	USD 2,359	29.44
2025-09-30	BUY	94	46.580	47.490	47.399	USD 4,456	29.24
2025-09-26	BUY	94	42.030	42.700	42.633	USD 4,008	29.08
2025-09-25	BUY	94	40.030	40.725	40.655	USD 3,822	29.02
2025-09-24	SELL	-842	41.040	41.400	41.364	USD -34,828	28.95 Loss of -10,453 on sale
2025-09-18	BUY	50	41.690	43.805	43.594	USD 2,180	28.88
2025-09-17	BUY	150	42.230	42.650	42.608	USD 6,391	28.80
2025-09-11	SELL	-50	40.810	42.020	41.899	USD -2,095	28.52 Loss of -669 on sale
2025-09-10	BUY	100	41.710	42.660	42.565	USD 4,256	28.44
2025-09-05	SELL	-50	41.980	42.080	42.070	USD -2,104	28.23 Loss of -692 on sale
2025-08-29	SELL	-150	38.630	38.870	38.846	USD -5,827	27.96 Loss of -1,632 on sale
2025-08-27	BUY	100	37.370	39.497	39.284	USD 3,928	27.84
2025-08-26	SELL	-50	38.640	39.550	39.459	USD -1,973	27.78 Loss of -584 on sale
2025-08-25	BUY	50	39.680	40.500	40.418	USD 2,021	27.70
2025-08-20	SELL	-196	38.540	38.720	38.702	USD -7,586	27.56 Loss of -2,185 on sale
2025-08-18	BUY	98	38.770	39.240	39.193	USD 3,841	27.42
2025-08-08	SELL	-98	34.680	35.570	35.481	USD -3,477	27.07 Loss of -824 on sale
2025-08-05	BUY	49	30.480	31.510	31.407	USD 1,539	26.99
2025-08-01	SELL	-147	29.960	31.590	31.427	USD -4,620	26.95 Loss of -658 on sale
2025-07-30	BUY	196	30.760	32.560	32.380	USD 6,346	26.91
2025-07-17	SELL	-98	34.570	35.870	35.740	USD -3,503	26.51 Loss of -905 on sale
2025-07-11	SELL	-392	34.690	35.948	35.822	USD -14,042	26.28 Loss of -3,742 on sale
2025-07-07	BUY	147	31.480	32.630	32.515	USD 4,780	26.07
2025-07-02	BUY	2,750	30.960	31.250	31.221	USD 85,858	25.92
2025-06-25	BUY	98	29.520	30.100	30.042	USD 2,944	25.79
2025-06-20	BUY	914	29.940	30.710	30.633	USD 27,999	25.68
2025-06-11	BUY	94	30.000	30.360	30.324	USD 2,850	25.44
2025-06-10	BUY	94	28.080	32.080	31.680	USD 2,978	25.42
2025-06-04	SELL	-47	29.190	30.230	30.126	USD -1,416	25.22 Loss of -231 on sale
2025-04-23	BUY	47	26.950	28.320	28.183	USD 1,325	24.08
2025-04-10	SELL	-376	18.540	19.940	19.800	USD -7,445	24.24 Profit of 1,669 on sale
2025-04-08	SELL	-47	18.320	20.740	20.498	USD -963	24.39 Profit of 183 on sale
2025-04-07	SELL	-47	19.500	21.490	21.291	USD -1,001	24.47 Profit of 149 on sale
2025-04-04	SELL	-235	21.180	22.020	21.936	USD -5,155	24.52 Profit of 608 on sale
2025-04-01	BUY	192	26.010	26.850	26.766	USD 5,139	24.48
2025-03-31	SELL	-141	25.710	25.830	25.818	USD -3,640	24.46 Loss of -192 on sale
2025-03-21	BUY	949	26.490	26.746	26.720	USD 25,358	24.25
2025-03-14	SELL	-704	25.450	25.770	25.738	USD -18,120	24.17 Loss of -1,106 on sale
2025-03-07	SELL	-88	23.680	23.920	23.896	USD -2,103	24.22 Profit of 28 on sale
2025-03-04	SELL	-44	21.510	22.130	22.068	USD -971	24.36 Profit of 101 on sale
2025-02-25	BUY	88	21.710	22.900	22.781	USD 2,005	24.74
2025-02-19	SELL	-44	24.840	25.150	25.119	USD -1,105	24.84 Loss of -12 on sale
2025-02-13	BUY	132	25.280	25.450	25.433	USD 3,357	24.80
2025-02-12	BUY	44	24.840	24.980	24.966	USD 1,099	24.80
2025-02-11	BUY	176	24.880	24.900	24.898	USD 4,382	24.79
2025-01-17	BUY	176	22.500	23.469	23.372	USD 4,113	24.38
2025-01-16	BUY	176	22.400	23.040	22.976	USD 4,044	24.66
2025-01-10	SELL	-88	23.210	25.821	25.560	USD -2,249	26.99 Profit of 126 on sale
2025-01-08	SELL	-176	26.340	27.180	27.096	USD -4,769	28.29 Profit of 210 on sale

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of LENZ

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy